[go: up one dir, main page]

PE20221909A1 - Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf - Google Patents

Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf

Info

Publication number
PE20221909A1
PE20221909A1 PE2022001462A PE2022001462A PE20221909A1 PE 20221909 A1 PE20221909 A1 PE 20221909A1 PE 2022001462 A PE2022001462 A PE 2022001462A PE 2022001462 A PE2022001462 A PE 2022001462A PE 20221909 A1 PE20221909 A1 PE 20221909A1
Authority
PE
Peru
Prior art keywords
seq
ligand trimer
antigen
binding molecules
molecules
Prior art date
Application number
PE2022001462A
Other languages
English (en)
Inventor
Maria Amann
Peter Bruenker
Christina Claus
Koller Claudia Ferrara
Sandra Grau-Richards
Christian Klein
Ekkehard Moessner
Joerg Thomas Regula
Pablo Umana
Viktor Levitski
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54695680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20221909(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20221909A1 publication Critical patent/PE20221909A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furniture Connections (AREA)
  • Connection Of Plates (AREA)

Abstract

Refiere a nuevas moleculas de union a antigeno que contienen un trimero de ligando de la familia de TNF, que comprenden (a) al menos una molecula Fab capaz de unirse especificamente a la proteina de activacion de fibroblastos (FAP); (b) un primer polipeptido que comprende dos ectodominios de 4-1BBL y un segundo polipeptido que comprende un ectodominio de 4-1BBL, los cuales estan unidos entre si por un enlace disulfuro y cuyas secuencias de aminoacidos se seleccionan del grupo comprendido por SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 96, SEQ ID NO: 373, SEQ ID NO: 374 y SEQ ID NO: 375, conectadas mediante un enlazador peptidico a los dominios CH3, VH-CL, entre otros; y (c) un dominio Fc de IgG1 o IgG4, compuesto por una primera y una segunda subunidad capaces de asociarse de manera estable. Asimismo, refiere a un metodo para producir estas nuevas moleculas y a una composicion farmaceutica que comprende dichas moleculas y al menos un excipiente farmaceuticamente aceptable.
PE2022001462A 2014-11-14 2015-11-13 Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf PE20221909A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14193260 2014-11-14
EP15183736 2015-09-03
EP15188142 2015-10-02
PCT/EP2015/076528 WO2016075278A1 (en) 2014-11-14 2015-11-13 Antigen binding molecules comprising a tnf family ligand trimer

Publications (1)

Publication Number Publication Date
PE20221909A1 true PE20221909A1 (es) 2022-12-23

Family

ID=54695680

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2022001462A PE20221909A1 (es) 2014-11-14 2015-11-13 Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf
PE2017000808A PE20170896A1 (es) 2014-11-14 2015-11-13 Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2017000808A PE20170896A1 (es) 2014-11-14 2015-11-13 Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf

Country Status (29)

Country Link
US (6) US10392445B2 (es)
EP (3) EP3489256B1 (es)
JP (2) JP6873901B2 (es)
KR (3) KR102877243B1 (es)
CN (4) CN114634570B (es)
AU (3) AU2015345024B2 (es)
CL (2) CL2017001000A1 (es)
CO (1) CO2017003212A2 (es)
CR (1) CR20170194A (es)
DK (2) DK3224275T3 (es)
EA (1) EA037557B1 (es)
ES (2) ES2871045T3 (es)
HR (2) HRP20200679T1 (es)
HU (2) HUE049982T2 (es)
IL (2) IL282922B (es)
LT (2) LT3224275T (es)
MA (2) MA40882B1 (es)
MX (2) MX391388B (es)
MY (1) MY191428A (es)
PE (2) PE20221909A1 (es)
PH (1) PH12017500892B1 (es)
PL (2) PL3489256T3 (es)
PT (1) PT3224275T (es)
RS (2) RS61870B1 (es)
SG (1) SG11201703597TA (es)
SI (2) SI3224275T1 (es)
TW (2) TWI757803B (es)
UA (1) UA125577C2 (es)
WO (1) WO2016075278A1 (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
KR20180023035A (ko) 2013-02-26 2018-03-06 로슈 글리카트 아게 이중특이적 t 세포 활성화 항원 결합 분자
US10633449B2 (en) 2013-03-27 2020-04-28 Cedars-Sinai Medical Center Treatment and reversal of fibrosis and inflammation by inhibition of the TL1A-DR3 signaling pathway
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
TWI757803B (zh) 2014-11-14 2022-03-11 瑞士商赫孚孟拉羅股份公司 包含tnf家族配位三聚體之抗原結合分子
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
EP3277305B1 (en) 2015-03-31 2021-07-21 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
AR106188A1 (es) * 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
WO2017055314A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
RS62258B1 (sr) 2015-10-02 2021-09-30 Hoffmann La Roche Bispecifična antitela specifična za pd1 i tim3
KR20180073561A (ko) * 2015-10-02 2018-07-02 에프. 호프만-라 로슈 아게 이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
KR20180053674A (ko) 2015-10-02 2018-05-23 에프. 호프만-라 로슈 아게 공자극 tnf 수용체에 특이적인 이중특이성 항체
MA43019A (fr) * 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps anti-humain cd19 à affinité élevée
EP3374399A1 (en) 2015-11-11 2018-09-19 Opi Vi- IP Holdco LLC Composition and methods for anti-tnfr2 antibodies
ES2837428T3 (es) 2016-01-08 2021-06-30 Hoffmann La Roche Procedimientos de tratamiento de cánceres positivos para CEA usando antagonistas de unión al eje PD-1 y anticuerpos biespecíficos anti-CEA/anti-CD3
WO2017161342A1 (en) 2016-03-17 2017-09-21 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through rnaset2
WO2017194442A1 (en) * 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
EP3243836A1 (en) * 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
EP3243832A1 (en) * 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
CN109952370B (zh) 2016-10-19 2023-09-08 豪夫迈·罗氏有限公司 用于产生免疫缀合物的方法
JP7194104B2 (ja) 2016-10-26 2022-12-21 シーダーズ―シナイ メディカル センター 抗ｔｌ１ａモノクローナル抗体の中和
CN110087682B (zh) * 2016-12-19 2023-12-15 豪夫迈·罗氏有限公司 用靶向性4-1bb(cd137)激动剂的组合疗法
JP7247091B2 (ja) * 2016-12-20 2023-03-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体と４－１ｂｂ（ｃｄ１３７）アゴニストの併用療法
EP3565843A1 (en) 2017-01-03 2019-11-13 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
AU2018205888B2 (en) 2017-01-05 2021-09-02 Kahr Medical Ltd. A PD1-41BBL fusion protein and methods of use thereof
SI3565828T1 (sl) 2017-01-05 2022-04-29 Kahr Medical Ltd. SIRP1 alfa-41BBL fuzijski protein in postopki za njegovo uporabo
WO2018151820A1 (en) * 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
JP7196094B2 (ja) 2017-03-29 2022-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
JP7205995B2 (ja) 2017-03-29 2023-01-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激性ｔｎｆ受容体に対する二重特異性抗原結合分子
JP7426825B2 (ja) 2017-04-03 2024-02-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－１抗体と突然変異ｉｌ－２とまたはｉｌ－１５とのイムノコンジュゲート
EP3606956B1 (en) 2017-04-04 2024-07-31 F. Hoffmann-La Roche AG Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
US11285207B2 (en) 2017-04-05 2022-03-29 Hoffmann-La Roche Inc. Bispecific antibodies specifically binding to PD1 and LAG3
US11643473B2 (en) 2017-04-24 2023-05-09 Alexion Pharmaceuticals, Inc. Antibody immune cell inhibitor fusion proteins
BR112019025792A2 (pt) 2017-06-07 2020-07-07 Spark Therapeutics, Inc. agentes de aperfeiçoamento para transfecção de células melhoradas e/ou produção de vetor raav
CN111246884A (zh) * 2017-11-01 2020-06-05 豪夫迈·罗氏有限公司 新颖的含有tnf家族配体三聚体的抗原结合分子
EP3502140A1 (en) * 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
CN110573531B (zh) * 2018-01-15 2021-04-02 天境生物科技(上海)有限公司 经修饰的Cκ和CH1结构域
MX2020009468A (es) * 2018-03-13 2020-10-22 Hoffmann La Roche Terapias de combinacion de agonistas de 4-1bb con anticuerpos anti-cd20.
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
BR112020016997A2 (pt) * 2018-04-13 2021-01-19 F. Hoffmann-La Roche Ag Moléculas de ligação e de ácido nucleico isolada, vetor, célula hospedeira, métodos para produzir a molécula de ligação, para tratar um indivíduo com câncer e para regular positivamente ou prolongar a atividade de células t, composição farmacêutica e uso da molécula de ligação
KR102763158B1 (ko) 2018-04-25 2025-02-04 프로메테우스 바이오사이언시즈, 인크. 최적화된 항tl1a 항체
CN112424228B (zh) * 2018-07-04 2024-08-09 豪夫迈·罗氏有限公司 新型双特异性激动性4-1bb抗原结合分子
CA3104780A1 (en) * 2018-07-11 2020-01-16 Kahr Medical Ltd. Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
US12286466B2 (en) * 2018-07-11 2025-04-29 Kahr Medical Ltd. PD1-4-1BBL variant fusion protein and methods of use thereof
EP3861026A1 (en) 2018-10-01 2021-08-11 F. Hoffmann-La Roche AG Bispecific antigen binding molecules comprising anti-fap clone 212
TWI839395B (zh) * 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
US11608376B2 (en) 2018-12-21 2023-03-21 Hoffmann-La Roche Inc. Tumor-targeted agonistic CD28 antigen binding molecules
US20200385488A1 (en) 2019-06-04 2020-12-10 Molecular Partners Ag Multispecific proteins
CA3140668A1 (en) * 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
CA3141039A1 (en) 2019-06-26 2020-12-30 Simon Auslaender Mammalian cell lines with sirt-1 gene knockout
BR112021026293A2 (pt) 2019-06-26 2022-03-03 Hoffmann La Roche Moléculas de ligação, anticorpos humanizados, ácido nucleico isolado, célula hospedeira, métodos para produzir a molécula de ligação ao antígeno, para tratar um indivíduo e suprarregular ou prolongar a atividade de células t citotóxicas, composição farmacêutica e uso da molécula
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
KR20220103721A (ko) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
WO2021209050A1 (en) * 2020-04-17 2021-10-21 Biocytogen Jiangsu Co., Ltd. Genetically modified non-human animal with human or chimeric tnfsf9 and/or 4-1bb
US20230212260A1 (en) 2020-05-15 2023-07-06 Apogenix Ag Multi-specific immune modulators
BR112022025856A2 (pt) 2020-06-19 2023-01-10 Hoffmann La Roche Anticorpo que se liga a cd3 e cd19, polinucleotídeo isolado, célula hospedeira, método de produção de um anticorpo que se liga a cd3 e cd19, composição farmacêutica, uso do anticorpo, método para tratar uma doença em um indivíduo e invenção
IL298921A (en) 2020-07-10 2023-02-01 Hoffmann La Roche Antibodies which bind to cancer cells and target radionuclides to said cells
KR20230066552A (ko) * 2020-07-24 2023-05-16 에프. 호프만-라 로슈 아게 항체-다량체-융합체의 발현 방법
MX2023008084A (es) 2021-01-12 2023-07-13 Hoffmann La Roche Anticuerpos split que se unen a celulas cancerosas y dirigen radionuclidos a dichas celulas.
WO2022152701A1 (en) 2021-01-13 2022-07-21 F. Hoffmann-La Roche Ag Combination therapy
EP4304723A1 (en) 2021-03-09 2024-01-17 F. Hoffmann-La Roche AG Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
BR112023025020A2 (pt) * 2021-06-01 2024-02-20 Janssen Biotech Inc Anticorpos anti-idiotípicos contra anticorpos anti-cd79b
EP4148067A1 (en) * 2021-09-08 2023-03-15 F. Hoffmann-La Roche AG Method for the expression of an antibody-multimer-fusion
WO2023073225A1 (en) 2021-11-01 2023-05-04 F. Hoffmann-La Roche Ag Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and a 4-1bb (cd137) agonist
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators
WO2023088889A1 (en) 2021-11-16 2023-05-25 Apogenix Ag CD137 ligands
CN118541382A (zh) 2021-12-14 2024-08-23 豪夫迈·罗氏有限公司 使用HLA-A2/MAGE-A4 x CD3双特异性抗体和4-1BB(CD137)激动剂治疗癌症
CN114349869B (zh) * 2021-12-20 2023-09-26 上海恩凯细胞技术有限公司 一种双特异性的nk细胞激动剂及制备方法和应用
CN114426585B (zh) * 2022-02-15 2023-10-03 广东香雪干细胞再生医学科技有限公司 融合蛋白及其表达细胞株与应用
CN116640226B (zh) * 2022-04-02 2024-04-26 广东东阳光药业股份有限公司 一种抑制宿主抗外源免疫细胞hvg反应的嵌合受体
CN114805564B (zh) * 2022-06-10 2023-06-06 郑州大学 特异性识别SARS-CoV-2 S蛋白NTD区域的单克隆抗体及应用
EP4587123A1 (en) 2022-09-15 2025-07-23 Avidicure IP B.V. Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
WO2024094741A1 (en) 2022-11-03 2024-05-10 F. Hoffmann-La Roche Ag Combination therapy with anti-cd19/anti-cd28 bispecific antibody
CN116574189A (zh) 2023-01-30 2023-08-11 北京智仁美博生物科技有限公司 针对人il-36r和/或人il-1r3的多种抗体及其用途
WO2024184287A1 (en) 2023-03-06 2024-09-12 F. Hoffmann-La Roche Ag Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
WO2024188966A1 (en) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-hla-g/anti-cd3 bispecific antibody and a 4‑1bb (cd137) agonist
CN118894934A (zh) 2023-05-05 2024-11-05 北京智仁美博生物科技有限公司 抗人il-15的抗体及其用途
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
WO2025140212A1 (en) * 2023-12-26 2025-07-03 Laekna Therapeutics Shanghai Co., Ltd. Multispecific binding agents comprising anti-fibroblast activation protein (fap) antibodies and one or more monovalent ligand traps and uses thereof
WO2025191139A1 (en) * 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of her2-specific antigen binding proteins and cytokines
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7802170A (nl) 1977-04-18 1978-10-20 Hitachi Metals Ltd Sierraad.
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1222292B1 (en) 1999-10-04 2005-08-31 Medicago Inc. Method for regulating transcription of foreign genes in the presence of nitrogen
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
CA2838062C (en) 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
NZ532526A (en) 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
EP2311867A1 (en) 2002-10-29 2011-04-20 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
WO2004069876A2 (en) 2003-02-06 2004-08-19 Micromet Ag Trimeric polypeptide construct to induce an enduring t cell response
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
AU2004253835B2 (en) 2003-07-04 2009-01-29 Affibody Ab Polypeptides having binding affinity for HER2
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
TR201809892T4 (tr) 2003-11-05 2018-07-23 Roche Glycart Ag Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2011265482B2 (en) * 2005-05-06 2013-08-29 Providence Health & Services - Oregon Trimeric OX40L-immunoglobulin fusion protein and methods of use
AU2013263717B2 (en) 2005-05-06 2016-05-19 Providence Health & Services - Oregon Trimeric OX40L-immunoglobulin fusion protein and methods of use
EP1736482A1 (en) 2005-06-20 2006-12-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Recombinant trimeric 4-1BBL
DE102005036542A1 (de) 2005-08-03 2007-02-08 Universität Stuttgart CTL-Prodrug
HRP20140331T1 (hr) 2006-08-14 2014-05-09 Xencor, Inc. Optimizirana antitijela usmjerena na cd19
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
EP2009022A1 (en) 2007-06-26 2008-12-31 Apogenix GmbH Trimeric death ligands with enhanced activity (tenascin)
GB0718843D0 (en) 2007-09-26 2007-11-07 Cancer Rec Tech Ltd Materials and methods relating to modifying the binding of antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
HRP20150425T1 (hr) * 2008-07-21 2015-06-05 Apogenix Gmbh Tnf sf jednolanäśane molekule
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
CA2769619C (en) 2009-08-17 2019-04-30 Roche Glycart Ag Targeted immunoconjugates
BR112012006326A2 (pt) 2009-09-29 2016-11-16 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, sequência de ácidos nucleicos, vetor de expressão, célula hospedeira procariótica ou eucariótica e invenção
PL2542590T5 (pl) 2010-03-05 2020-08-10 The Johns Hopkins University Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
US8552024B2 (en) 2010-08-13 2013-10-08 Hoffman-La Roche Inc. Azacyclic compounds
HUE036077T2 (hu) 2010-08-13 2018-06-28 Roche Glycart Ag Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
SI2691417T2 (sl) 2011-03-29 2025-05-30 Roche Glycart Ag FC variante protitelesa
CA2831820C (en) 2011-04-01 2021-05-25 Universitat Stuttgart Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
JP2013055204A (ja) 2011-09-02 2013-03-21 Toshiba Corp 半導体記憶装置
NZ701821A (en) 2012-04-30 2016-06-24 Biocon Ltd Targeted/immunomodulatory fusion proteins and methods for making same
SG11201408526SA (en) 2012-08-08 2015-03-30 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
KR20180023035A (ko) * 2013-02-26 2018-03-06 로슈 글리카트 아게 이중특이적 t 세포 활성화 항원 결합 분자
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP2994487B1 (en) 2013-05-07 2019-10-09 F.Hoffmann-La Roche Ag Trimeric antigen binding molecules
WO2015117930A1 (en) 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
JP6666267B2 (ja) 2014-05-29 2020-03-13 メディミューン，エルエルシー Ｏｘ４０ｌ融合タンパク質およびその使用
SG10201913324PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
TWI757803B (zh) 2014-11-14 2022-03-11 瑞士商赫孚孟拉羅股份公司 包含tnf家族配位三聚體之抗原結合分子
EP3277305B1 (en) 2015-03-31 2021-07-21 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
WO2017055314A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
MA43019A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps anti-humain cd19 à affinité élevée
EP3356420B1 (en) 2015-10-02 2023-11-01 F. Hoffmann-La Roche AG Multispecific antibodies
KR20180053674A (ko) 2015-10-02 2018-05-23 에프. 호프만-라 로슈 아게 공자극 tnf 수용체에 특이적인 이중특이성 항체
EP3359568B1 (en) 2015-10-07 2022-03-09 F. Hoffmann-La Roche AG Bispecific antibodies with tetravalency for a costimulatory tnf receptor
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
WO2017194442A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
JP6768917B2 (ja) 2016-07-08 2020-10-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ラボラトリ試料を処理するための装置、ラボラトリオートメーションシステム、およびラボラトリ試料をピペット操作するための方法
CN110087682B (zh) 2016-12-19 2023-12-15 豪夫迈·罗氏有限公司 用靶向性4-1bb(cd137)激动剂的组合疗法
JP7247091B2 (ja) 2016-12-20 2023-03-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体と４－１ｂｂ（ｃｄ１３７）アゴニストの併用療法
EP3565843A1 (en) 2017-01-03 2019-11-13 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
JP7205995B2 (ja) 2017-03-29 2023-01-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激性ｔｎｆ受容体に対する二重特異性抗原結合分子
JP7196094B2 (ja) 2017-03-29 2022-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
EP3606956B1 (en) 2017-04-04 2024-07-31 F. Hoffmann-La Roche AG Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
CN111246884A (zh) 2017-11-01 2020-06-05 豪夫迈·罗氏有限公司 新颖的含有tnf家族配体三聚体的抗原结合分子
BR112020006443A2 (pt) 2017-11-01 2020-09-29 F. Hoffmann-La Roche Ag anticorpos biespecíficos, ácido nucleico isolado, vetor ou célula hospedeira, método para produzir um anticorpo biespecífico e para tratar um indivíduo, composição farmacêutica e uso do anticorpo
MX2020009468A (es) 2018-03-13 2020-10-22 Hoffmann La Roche Terapias de combinacion de agonistas de 4-1bb con anticuerpos anti-cd20.
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
BR112020016997A2 (pt) 2018-04-13 2021-01-19 F. Hoffmann-La Roche Ag Moléculas de ligação e de ácido nucleico isolada, vetor, célula hospedeira, métodos para produzir a molécula de ligação, para tratar um indivíduo com câncer e para regular positivamente ou prolongar a atividade de células t, composição farmacêutica e uso da molécula de ligação
CN112424228B (zh) 2018-07-04 2024-08-09 豪夫迈·罗氏有限公司 新型双特异性激动性4-1bb抗原结合分子
EP3861026A1 (en) 2018-10-01 2021-08-11 F. Hoffmann-La Roche AG Bispecific antigen binding molecules comprising anti-fap clone 212
EP3861025A1 (en) 2018-10-01 2021-08-11 F. Hoffmann-La Roche AG Bispecific antigen binding molecules with trivalent binding to cd40
WO2020208049A1 (en) 2019-04-12 2020-10-15 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising lipocalin muteins
BR112021026293A2 (pt) 2019-06-26 2022-03-03 Hoffmann La Roche Moléculas de ligação, anticorpos humanizados, ácido nucleico isolado, célula hospedeira, métodos para produzir a molécula de ligação ao antígeno, para tratar um indivíduo e suprarregular ou prolongar a atividade de células t citotóxicas, composição farmacêutica e uso da molécula
CA3162009A1 (en) 2020-01-09 2021-07-15 F. Hoffmann-La Roche Ag New 4-1bbl trimer-containing antigen binding molecules
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap

Also Published As

Publication number Publication date
PE20170896A1 (es) 2017-07-12
CN113372434B (zh) 2024-06-04
MA40882B1 (fr) 2020-05-29
AU2022201144A1 (en) 2022-03-17
SI3224275T1 (sl) 2020-07-31
MX391388B (es) 2025-03-21
ES2871045T3 (es) 2021-10-28
HRP20210739T1 (hr) 2021-06-25
UA125577C2 (uk) 2022-04-27
LT3224275T (lt) 2020-05-25
KR20250158074A (ko) 2025-11-05
CN113372434A (zh) 2021-09-10
US20190382507A1 (en) 2019-12-19
AU2022201144B2 (en) 2025-03-06
EA201791057A1 (ru) 2017-10-31
EP3738609B1 (en) 2025-06-18
WO2016075278A1 (en) 2016-05-19
CN120574325A (zh) 2025-09-02
HUE054122T2 (hu) 2021-08-30
HRP20200679T1 (hr) 2020-07-24
MA40882A (fr) 2017-10-04
JP2018503356A (ja) 2018-02-08
PT3224275T (pt) 2020-05-04
KR102588377B1 (ko) 2023-10-12
TWI713474B (zh) 2020-12-21
JP7184938B2 (ja) 2022-12-06
NZ767674A (en) 2024-07-05
HK1255482A1 (zh) 2019-08-16
PL3489256T3 (pl) 2021-08-23
IL282922A (en) 2021-06-30
US20220259326A1 (en) 2022-08-18
RS61870B1 (sr) 2021-06-30
EP3489256B1 (en) 2021-03-17
EP3489256A1 (en) 2019-05-29
CO2017003212A2 (es) 2017-09-20
CL2019003728A1 (es) 2020-07-17
MX2020012798A (es) 2022-04-07
AU2015345024B2 (en) 2020-10-15
IL251317A0 (en) 2017-05-29
JP2021097674A (ja) 2021-07-01
IL282922B (en) 2022-08-01
IL251317B (en) 2021-05-31
PH12017500892B1 (en) 2023-08-18
ES2788979T3 (es) 2020-10-23
BR112017009006A2 (pt) 2018-04-10
TWI757803B (zh) 2022-03-11
US20200247904A1 (en) 2020-08-06
EP3224275B1 (en) 2020-03-04
KR102877243B1 (ko) 2025-10-29
EA037557B1 (ru) 2021-04-14
CA2963718A1 (en) 2016-05-19
US12441812B2 (en) 2025-10-14
CN108064237B (zh) 2022-02-11
LT3489256T (lt) 2021-06-10
TW202041527A (zh) 2020-11-16
US10392445B2 (en) 2019-08-27
SI3489256T1 (sl) 2021-08-31
MY191428A (en) 2022-06-27
AU2015345024A1 (en) 2017-04-20
PH12017500892A1 (en) 2017-11-06
EP3738609A1 (en) 2020-11-18
MX380253B (es) 2025-03-12
KR20170085552A (ko) 2017-07-24
CL2017001000A1 (es) 2018-01-12
AU2020264337A1 (en) 2021-01-28
NZ767672A (en) 2024-02-23
JP6873901B2 (ja) 2021-05-19
US11267903B2 (en) 2022-03-08
HUE049982T2 (hu) 2020-11-30
RS60201B1 (sr) 2020-06-30
TW201629094A (zh) 2016-08-16
KR20230146133A (ko) 2023-10-18
US20250101135A1 (en) 2025-03-27
CR20170194A (es) 2017-07-10
CN108064237A (zh) 2018-05-22
NZ730933A (en) 2024-02-23
US20220259327A1 (en) 2022-08-18
CN114634570B (zh) 2025-05-06
US20160200833A1 (en) 2016-07-14
EP3738609C0 (en) 2025-06-18
AU2020264337B2 (en) 2021-12-02
MX2017006250A (es) 2017-11-17
EP3224275A1 (en) 2017-10-04
SG11201703597TA (en) 2017-06-29
PL3224275T3 (pl) 2020-09-07
DK3489256T3 (da) 2021-05-25
DK3224275T3 (da) 2020-05-04
CN114634570A (zh) 2022-06-17
US11306154B2 (en) 2022-04-19
MA53242A (fr) 2021-06-23

Similar Documents

Publication Publication Date Title
PE20221909A1 (es) Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf
PE20240096A1 (es) Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
CO2020000357A2 (es) Receptores de células t novedosos, e inmunoterapia usando los mismos
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
MX395287B (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
PE20190436A1 (es) Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf y un resto de union a pd1
JP2017529067A5 (es)
PE20140218A1 (es) Composicion farmaceutica
CL2013003634A1 (es) Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso
BR112019021991A2 (pt) Proteínas de ligação ao antígeno trem2 e seus usos
JP2019506841A5 (es)
NZ750366A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
HRP20191704T1 (hr) Multispecifična protutijela
AR095432A1 (es) Proteínas de unión a antígeno
FI4050034T3 (fi) Cd3:een sitoutuvia vasta-aineita
CO6331370A2 (es) Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
ES2691091T3 (es) Vacuna conjugada de péptido antigénico de WT1
RU2021124437A (ru) Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования
AR108452A1 (es) Moléculas de unión a antígeno que comprenden un trímero ligando de la familia de fnt y una fracción de unión a tenascina
EP4296673A3 (en) Peptides and methods for the detection of lyme disease antibodies
RU2022102250A (ru) Клетка
JP2014505463A5 (es)
HRP20220960T1 (hr) Kimerni proteini faktora viii i njihova upotreba
HRP20220649T1 (hr) Novi bispecifični format pogodan za upotrebu u visokopropusnom skriningu